Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study

American Heart Journal

Volumn 156, Issue 5, 2008, Pages

  Keaney Jr , John F ^a   Lipinska, Izabella ^a   Larson, Martin G ^b   Dupuis, Josée ^c   Freedman, Jane E ^a   Hamburg, Naomi M ^a   Massaro, Joseph M ^a,c   Rong, Jian ^b   Sutherland, Patrice ^b   Vita, Joseph A ^a   Vasan, Ramachandran S ^a,b   Benjamin, Emelia J ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENETIC LINKAGE; HEREDITY; HERITABILITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL MODEL;

EID: 54349093968     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.06.041     Document Type: Article

References (39)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Cybulsky M.I., and Gimbrone Jr. M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251 (1991) 788-791
3. van der Wal A.C., Becker A.E., van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
4. Waters D., Craven T.E., and Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993) 1067-1075
5. Davies M.J., and Thomas A.C. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 53 (1985) 363-373
6. Hollenbaugh D., Ochs H.D., Noelle R.J., et al. The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 138 (1994) 23-37
7. Karmann K., Hughes C.C., Schechner J., et al. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 92 (1995) 4342-4346
8. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
9. Mach F., Schonbeck U., Sukhova G.K., et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
10. Lutgens E., Gorelik L., Daemen M.J., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 5 (1999) 1313-1316
11. Schonbeck U., Varo N., Libby P., et al. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
12. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
13. Quan S.F., Howard B.V., Iber C., et al. The Sleep Heart Health Study: design, rationale, and methods. Sleep 20 (1997) 1077-1085
14. In: Kannel W.B., Wolf P.A., and Garrison R.J. (Eds). The Framingham Study: an epidemiological investigation of cardiovascular disease, section 34 (1987), National Heart, Lung, and Blood Institute, Bethesda (MD) NIH publication 87-2703.
15. Kleinbaum D.G., Kupper L.L., and Muller K.E. Applied regression analysis and other multivariable methods. 2nd ed. (1988), PWS-Kent, Boston
16. SAS/STAT User's Guide, Version 8 (1999), SAS Institute, Inc, Cary (NC)
17. Almasy L., and Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62 (1998) 1198-1211
18. Allison D.B., Neale M.C., Zannolli R., et al. Testing the robustness of the likelihood-ratio test in a variance-component quantitative-trait loci-mapping procedure. Am J Hum Genet 65 (1999) 531-544
19. Dupuis J., Larson M.G., Vasan R.S., et al. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q. Atherosclerosis 182 (2005) 307-314
20. Slupsky J.R., Kalbas M., Willuweit A., et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 80 (1998) 1008-1014
21. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
22. Vita J.A., and Keaney Jr. J.F. Endothelial function: a barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
23. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
24. Kinlay S., Schwartz G.G., Olsson A.G., et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110 (2004) 386-391
25. Heeschen C., Dimmeler S., Hamm C.W., et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 45 (2005) 229-237
26. Garlichs C.D., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
27. Schonbeck U., Gerdes N., Varo N., et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 106 (2002) 2888-2893
28. Semb A.G., van W.S., Ueland T., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41 (2003) 275-279
29. Varo N., Vicent D., Libby P., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107 (2003) 2664-2669
30. Marx N., Imhof A., Froehlich J., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107 (2003) 1954-1957
31. de Lemos J.A., Zirlik A., Schonbeck U., et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 25 (2005) 2192-2196
32. Ferrari S., Giliani S., Insalaco A., et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A 98 (2001) 12614-12619
33. Winkelstein J.A., Marino M.C., Ochs H., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82 (2003) 373-384
34. Ahn E.R., Lander G., Jy W., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148
35. Bereczki D., Nagy E., Pal A., et al. Should soluble CD40 ligand be measured from serum or plasma samples. Arterioscler Thromb Vasc Biol 23 (2003) 1129-1130
36. Thom J., Gilmore G., Yi Q., et al. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2 (2004) 2067-2069
37. Mason P.J., Chakrabarti S., Albers A.A., et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96 (2005) 1365-1369
38. Keaney Jr. J.F. Circulating biomarkers in acute coronary syndromes: something different or more of the same. Circulation 112 (2005) 778-780
39. Eaton S.M., Burns E.M., Kusser K., et al. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med 200 (2004) 1613-1622